Vectura was established in 1997 to identify and develop opportunities in drug formulation and delivery.  Vectura has evolved into a product development company that focuses on the development of pharmaceutical therapies for airways diseases.



Global development and licence agreement with Janssen Biotech, VR096, announced. 

VR942 Phase I Clinical study commenced.  Ongoing EU/RoW launches of AirFluSal® Forspiro® by Sandoz continue.  Vectura announces successful pre-IND meeting with the US FDA regarding VR647.  Further development milestones received on generics pipeline programmes, VR315 and VR632 and further progress on pipeline programmes with milestones paid on VR876, VR632 and completion of target enrolment of the first-in-infant Phase I/IIa safety study by Ablynx on the VR465 programme.  Novartis confirmed commencement of first Phase III trial of inhaled triple therapy QVM149 for asthma triggering a milestone payment to Vectura and the US FDA approved Utibron™ Neohaler® (QVA149) and Seebri™ Neohaler® (NVA237).


AirFluSal® Forspiro® launched in the EU by Sandoz. Vectura acquired Activaero GmbH and raised £52m. Vectura signs a further US collaboration agreement with a leading international pharmaceutical company (existing undisclosed partner for VR315 US) for the VR506 asthma therapy. Novartis submit regulatory applications to US FDA for QVA149 and NVA237


Ultibro® Breezhaler® (QVA149) and Seebri® Breezhaler® (NVA237) launched by Novartis in EU and Japan. Establishment of Kinnovata joint venture in China. Initiated co-development deal with UCB for a novel molecule, VR942. Our partner Sandoz granted first marketing authorisation for AirFluSal® Forspiro® (VR315 EU & ROW) in Denmark


Seebri® Breezhaler® (NVA237) approved in EU and Japan. Novartis announces positive Phase III data for QVA149


Novartis announces positive NVA237 Phase III data and files in Europe and Japan. In August, Vectura licenses VR315 ROW rights to Sandoz and VR315 US rights to an undisclosed partner


Vectura regains US rights to VR315 from Sandoz.  GSK licenses some of Vectura’s dry powder drug formulation patents. Vectura closes laboratory facilities in Nottingham and consolidates formulation activities on the Chippenham site


Vectura's partner Novartis commenced Phase III studies with NVA237 triggering milestone payment


Vectura and its partners announce positive Phase II data for NVA237. Sandoz was confirmed as partner for the generic asthma/COPD product VR315


Vectura acquired Innovata plc. In July, Vectura moves from AIM to the Official List on the London Stock Exchange


Institutional placing raising £45m.  Vectura signed partner agreement with Sandoz for VR315 - EU and US


Vectura entered into its first global commercialisation and development agreement with Novartis for NVA237


Vectura is listed on the London Stock Exchange on AIM


Vectura acquired the Aspirair® inhaler technology and associated device engineering team from Cambridge Consultants Ltd.  Vectura moved to its current head office in Chippenham, Wiltshire, UK


Vectura signed a collaboration with Arakis Ltd (later acquired by Sosei) in the development of AD237 (later NVA237) for the treatment of COPD


Founded by Merlin and then acquired operations from Bath University through issues of shares. Vectura also acquired Co-ordinated Drug Development Limited and the Centre for Drug Formulation Studies. These acquisitions provided formulation expertise, an intellectual property estate, a development services business, and a team of research scientists